Already FDA-approved for Parkinson’s and other movement disorders, DBS acts like a “pacemaker for the brain,” using implanted electrodes to deliver precise electrical pulses. While still in the clinical trial phase for mental health (including the national TRANSCEND trial), early data suggests that by targeting the brain’s “white matter” communication highways, DBS can help “unstick” a brain trapped in a chronic depressive state.
Key Facts
- The “Unstucking” Goal: DBS for depression is not a “happy switch.” Instead, it aims to reduce biological barriers, allowing the brain to move out of a stagnant, depressed state so patients can once again engage in meaningful life activities.
- White Matter vs. Gray Matter: Unlike Parkinson’s treatment (which targets gray matter), depression DBS targets white matter—the brain’s communication highways. Because of this, the effects are more gradual, often taking weeks or months to unfold.
- The TRANSCEND Trial: UTSW is a site for this gold-standard, double-blind study. To ensure total objectivity, neither the patients nor the doctors know who is receiving active stimulation during the initial study phase.
- Eligibility: Candidates typically include adults who have not responded to four or more treatments and have a history of severe, long-term depressive episodes.
Read Full Article Here
